Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02184572 · ClinicalTrials.gov registry record · Phase 3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

A Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
1,742
Enrollment target
20
Study locations

NCT02184572: Completed Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella, sponsored by GlaxoSmithKline.

NCT02184572 is a Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,742 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02184572, a Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
1,742 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.

Primary Outcome

Fever was assessed for temperature equal to/above (≥) 38.0°C and above (\>) 39.0°C. The safety profile for fever was assessed based on the group difference (INV\_MMR minus COM\_MMR) in incidence of fever equal to or below the cut-off value.

Conditions Studied

Measles-Mumps-Rubella Vaccine Measles; Mumps; Rubella

Interventions

  • BIOLOGICAL Priorix
  • BIOLOGICAL M-M-R II
  • BIOLOGICAL Varivax
  • BIOLOGICAL Havrix
  • BIOLOGICAL Prevnar 13

Study Locations (20)

California

  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Baldwin Park
  • GSK Investigational Site - Daly City
  • GSK Investigational Site - Fresno
  • GSK Investigational Site - Hayward
  • GSK Investigational Site - Oakland
  • GSK Investigational Site - Paramount
  • GSK Investigational Site - Pleasanton
  • GSK Investigational Site - Roseville
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - San Jose
  • GSK Investigational Site - Santa Clara
  • GSK Investigational Site - Walnut Creek

Arkansas

  • GSK Investigational Site - Fayetteville
  • GSK Investigational Site - Jonesboro

Alabama

  • GSK Investigational Site - Birmingham

Arizona

  • GSK Investigational Site - Tucson

Colorado

  • GSK Investigational Site - Colorado Springs

Connecticut

  • GSK Investigational Site - Norwich

Trial Details

FieldValue
Enrollment Target 1,742 participants
Start Date 2014-08-25
Est. Completion 2015-12-22
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What the finished NCT02184572 record still lists

NCT02184572 is an interventional study that assigns participants to a tested intervention. Its 1,742 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (126% higher).

The record links to 2 conditions, with Measles-Mumps-Rubella Vaccine appearing as the primary indexed condition, and to 5 interventions - of which Priorix is the first listed.

NCT02184572 names 20 study sites across 6 states, led by California, Arkansas, Alabama.

Frequently Asked Questions

What is clinical trial NCT02184572 about?

NCT02184572 is a clinical study titled "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age". The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.

What is the current status of trial NCT02184572?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,742 participants. The study started on 2014-08-25. Estimated completion is 2015-12-22.

What conditions does trial NCT02184572 study?

This clinical trial studies the following conditions: Measles-Mumps-Rubella Vaccine, Measles; Mumps; Rubella.

What interventions are being tested in trial NCT02184572?

The interventions under investigation include: Priorix (BIOLOGICAL), M-M-R II (BIOLOGICAL), Varivax (BIOLOGICAL), Havrix (BIOLOGICAL), Prevnar 13 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02184572?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02184572 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Measles-Mumps-Rubella Vaccine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02184572's enrollment target sits among peer trials

1,742 129th of 2000 higher than 1,872 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04712656 · 1,739 participants

    Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea

  • NCT05934487 · 1,750 participants · NA

    PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

  • NCT06954337 · 1,750 participants · NA

    MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

  • NCT07183527 · 1,750 participants · NA

    Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02184572, the US trial registry maintained by the National Library of Medicine. NCT02184572 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.